FDA Approves Adcetris With Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma

The FDA has approved brentuximab vedotin (Adcetris, Seagen, a subsidiary of Pfizer) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse LBCL (DLBCL) not otherwise specified, DLBCL arising from indolent lymphoma or high-grade B-cell lymphoma, after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen